REVERSED INNOVATION
We find new indications for existing technologies
THE MEANING OF
REVERSED INNOVATION
We find new indications for existing technologies.
Through our research, we work relentlessly to improve lives by addressing unmet medical needs.
Reversed Innovation is our core value. It reflects our commitment to transforming existing products or technologies to solve new, previously overlooked, or underexplored medical challenges.
As a leader in the biopharmaceutical industry, Reversed Innovation aligns with our broader mission: to repurpose proven solutions in novel ways that deliver meaningful impact for patients worldwide.
TRUSTED DEVELOPMENT
Dr. Claus J. Møller-San Pedro is the company CEO. Dr. Møller co-founded and participated in securing successful IPOs of 3 companies in the BioPharma Industry:
- OXiGENE Inc. (OTLC)
- Genmab A/S (GMAB)
- Y-mAbs Therapeutics, Inc. (YMAB)
NEWS
Granted U.S. Patent for Intranasal Ketamine Treatment of Cluster Headache
Hørsholm, Denmark – September 21, 2026 AFYX Therapeutics Granted U.S. Patent for Intranasal Ketamine Treatment of Cluster Headache AFYX Therapeutics A/S today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,734,136, entitled...
EU Approval – Misoprostol Tablet for Induction of Labour
AFYX Therapeutics Receives EU Approval for Its Low-Dose Oral Misoprostol Tablet for Induction of Labour in 20 European Countries and Northern Ireland. Hørsholm, Denmark – 4 May 2026 AFYX Therapeutics A/S (“AFYX”), a Danish specialty pharmaceutical company focused on...
AFYX Therapeutics enters strategic partnership with Adcock Ingram Critical Care
PRESS RELEASE AFYX Therapeutics enters strategic partnership with Adcock Ingram Critical Care for distribution in South Africa and Sub-Saharan Africa. Copenhagen, Denmark – January 22, 2026. AFYX Therapeutics has entered a strategic distribution partnership with...
AFYX THERAPEUTICS HQ
Slotsmarken 11, 1.tv.
DK-2970 Hørsholm
Denmark
VAT: 38793594
Phone: +45 7174 7174
info@afyxtx.com
AFYX NORWAY
Gaustadalléen 21
NO-0349 Oslo
Norway
VAT: 922 558 221
Phone: +47 2396 7174